| Literature DB >> 8157474 |
T R Jenkins1, C Tangen, J S Macdonald, G Weiss, R Chapman, A Hantel.
Abstract
Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m2 intravenously every 21 days. No objective responses were observed (95% confidence interval 0%-10%). Toxicities of grade > or = 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.Entities:
Mesh：
Substances：
Year: 1993 PMID： 8157474 DOI： 10.1007/bf00874432
Source DB: PubMed Journal: Invest New Drugs ISSN： 0167-6997 Impact factor: 3.850